You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A new study is inspiring hope for treating children born with progeria, a rare, fatal genetic disease that causes symptoms much like early aging. In mice with a progeria-causing mutation, a cousin of the celebrated genome editor known as CRISPR corrected the DNA mistake, preventing the heart damage typical of the disease, a research team reports this week in Nature. Treated mice lived about 500 days, more than twice as long as untreated animals. Although developers of the progeria therapy aim to improve it, they are also taking steps toward testing the current version in affected kids and some other scientists endorse a rush.
